ArticleCancer biology & therapy2018

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Laurence Booth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.